Roxadustat is named as an intervention in 3 current clinical trials in our China, Ireland and UK registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Astellas Pharma Global Development, Inc (1). The most-studied condition is Chronic Kidney Disease.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
NCT05970172 · Chronic Kidney Disease, Renal Anemia
|
Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | Ireland, UK |
|
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease
NCT07268807 · ClinicalTrials.gov ↗ · Heart Failure, CKD, Anemia
|
Observational | Not yet open | Zhongda Hospital | China |
|
Effect of Perioperative Roxadustat in Elective Lumbar Interbody Fusion Surgery.
NCT06772272 · ClinicalTrials.gov ↗ · Perioperative Anemia
|
Phase 3 | Active, closed | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Astellas Pharma Global Development, Inc. | 1 |
| Zhongda Hospital | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
| Clinical trials in Ireland | 1 | 1 |
| Clinical trials in UK | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China, Ireland and UK registers name Roxadustat (also registered as FG-4592) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in Ireland and 1 with sites in UK. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Astellas Pharma Global Development, Inc (1), Zhongda Hospital (1) and Second Affiliated Hospital, Zhejiang University, School of Medicine (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Roxadustat works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Roxadustat works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Roxadustat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.